Home » PDL BIOPHARMA ANNOUNCES ROCHE DISCONTINUATION OF CO-DEVELOPMENT OF DACLIZUMAB IN ASTHMA
PDL BIOPHARMA ANNOUNCES ROCHE DISCONTINUATION OF CO-DEVELOPMENT OF DACLIZUMAB IN ASTHMA
September 5, 2006
BioPharma, Inc. announced that Roche has discontinued its involvement in the development of daclizumab in asthma, which both companies had been co-developing since 2004. The decision, following a portfolio review at Roche, has no effect on the companies' ongoing collaboration to co-develop daclizumab in transplant maintenance, and the companies intend to proceed with planned Phase 2 studies for the transplant indication during 2007. Pipeline Review (http://www.pipelinereview.com/joomla/content/view/6113/101/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct